Evommune (EVMN) Operating Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Operating Expenses data on file, last reported at $24.0 million in Q1 2026.

• Quarterly Operating Expenses rose 32.84% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.0 million (changed N/A YoY) and the FY2025 annual result came in at $94.1 million, up 22.15% from the prior year.
• Operating Expenses retreated to $24.0 million in Q1 2026 per EVMN's latest filing, from $29.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $29.7 million in Q4 2025 and bottomed at $16.5 million in Q3 2024.
• The 3-year median for Operating Expenses is $22.4 million (2024), against an average of $22.2 million.
• The widest annual swing landed in 2025, when Operating Expenses jumped 41.24%; it then surged 32.84% in 2026.
• Tracing EVMN's Operating Expenses over 3 years: stood at $21.5 million in 2024, then surged by 38.51% to $29.7 million in 2025, then dropped by 19.39% to $24.0 million in 2026.
• Per Business Quant, the three latest EVMN Operating Expenses figures stand at $24.0 million (Q1 2026), $29.7 million (Q4 2025), and $23.3 million (Q3 2025).

Peer Comparison